[ACST] Acasti Pharma, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 14.14 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.33 Change: 0.17 (14.65%)
Ext. hours: Change: 0 (0%)

chart ACST

Refresh chart

Strongest Trends Summary For ACST

ACST is in the long-term down -97% below S&P in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.

Fundamental Ratios
Shares Outstanding10.71 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit Operating Profit Total Assets Total Current Assets
Total Current Liabilities Total Debt Total Liabilities Total Revenue
Technical Data
High 52 week3.1 Low 52 week0.63 Last close0.71 Last change1.59%
RSI36.35 Average true range0.04 Beta0.3 Volume4.94 M
Simple moving average 20 days-2.49% Simple moving average 50 days-23.16% Simple moving average 200 days-39.8%
Performance Data
Performance Week7.92% Performance Month-34.26% Performance Quart-31.73% Performance Half-44.96%
Performance Year-43.2% Performance Year-to-date-24.69% Volatility daily6.55% Volatility weekly14.65%
Volatility monthly30.03% Volatility yearly104.04% Relative Volume5202.7% Average Volume196.58 K
New High New Low


2019-10-01 09:00:00 | Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

2019-09-30 08:35:00 | Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020

2019-09-27 06:05:30 | Do Insiders Own Lots Of Shares In Acasti Pharma Inc. CVE:ACST?

2019-09-09 08:30:00 | Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity

2019-09-04 09:00:00 | Acasti Pharma to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 9th

2019-08-28 16:05:00 | Acasti Pharma Announces the Election of Its Directors, Amendments to Its Stock Option and Equity Incentive Plans and Other Related Matters Approved at Its AGM

2019-08-14 08:00:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2020

2019-08-09 08:00:00 | Acasti Pharma Co-Founder, Chief Operating and Scientific Officer to Participate on Lipid Panel at the 2019 BTIG Biotechnology Conference

2019-08-07 08:00:00 | Acasti Pharma Schedules First Quarter Fiscal 2020 Conference Call

2019-07-25 15:42:52 | Acasti Pharma Comments on Trading Activity and Reaffirms No Plans to Raise Capital

2019-07-05 08:35:12 | Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

2019-06-26 11:08:45 | Acasti Pharma Trades Higher Despite 'Material Uncertainty'

2019-06-26 11:00:00 | Acasti Pharma, Inc. to Host Earnings Call

2019-06-26 08:05:00 | Acasti Pharma Provides Fiscal 2019 Year-End Business Update

2019-06-24 09:00:00 | Acasti Pharma Awarded Notice of Allowance for a Second Patent in China Covering CaPre’s Omega-3 Phospholipid Composition

2019-06-19 08:00:00 | Acasti Pharma Schedules Fourth Quarter and Fiscal 2019 Conference Call

2019-06-04 09:15:00 | Acasti Pharma Announces TRILOGY 2 Trial Has Achieved its 100% Patient Randomization Target in Patients with Severe Hypertriglyceridemia

2019-05-23 17:00:00 | Acasti Issues Shares in Settlement of Claims with Former Chief Executive Officer

2019-05-21 07:30:00 | Acasti Pharma to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

2019-05-15 07:55:00 | Acasti Pharma Awarded Notices of Allowance for Additional Composition & Use Patents in Mexico, Chile and Israel

2019-05-10 07:30:00 | Acasti Settles Claims with Former Chief Executive Officer

2019-04-24 08:00:00 | Acasti Pharma CEO to Present at the ThinkEquity Conference on May 2nd in New York City

2019-04-15 09:15:00 | Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia

2019-04-01 09:20:53 | Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal

2019-03-26 08:30:00 | Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd

2019-03-13 08:30:00 | Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th

2019-02-21 09:15:00 | Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50

2019-02-14 14:57:21 | Acasti: Fiscal 3Q Earnings Snapshot

2019-02-14 08:05:00 | Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

2019-02-08 08:00:00 | Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call

2019-01-09 11:58:00 | 4 Healthcare Stocks Looking To Set January Highs

2019-01-09 08:00:00 | Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office

2018-12-31 08:00:00 | Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients >20% Have Completed Their 6 Month Treatment Plan

2018-12-28 09:55:02 | Generic Industry on Path to Recovery: 3 Hot Picks for 2019

2018-12-20 08:00:00 | Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia

2018-11-27 07:00:00 | Acasti Pharma to Present at the 11th Annual LD Micro Main Event

2018-11-14 08:53:13 | Acasti: Fiscal 2Q Earnings Snapshot

2018-11-14 08:00:00 | Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019

2018-11-07 08:00:00 | Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call

2018-10-23 09:00:11 | Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option

2018-10-11 07:30:00 | Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares

2018-10-10 08:05:00 | Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review

2018-10-04 09:35:40 | Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares

2018-10-04 07:59:50 | The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut

2018-10-03 16:23:12 | Acasti Pharma Announces Public Equity Offering

2018-10-03 16:23:11 | Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares

2018-10-02 09:10:25 | The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares

2018-10-01 17:00:00 | Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

2018-09-28 08:17:00 | Today’s Research Reports on Stocks to Watch: Achieve Life Sciences and Acasti Pharma

2018-09-24 08:00:00 | Acasti Pharma Appoints Jean-François Boily as Vice President of Finance